BTLA/CD272 Antibody (330104) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # FAB3354M
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Monoclonal Rat IgG2A Clone # 330104
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human BTLA
Ile25-Ser150
Accession # AAP44003
Ile25-Ser150
Accession # AAP44003
Specificity
Detects human BTLA in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse BTLA or recombinant human HVEM is observed.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2A
Applications for BTLA/CD272 Antibody (330104) [DyLight 594]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: BTLA
Long Name
B- And T-Lymphocyte Attenuator
Alternate Names
CD272
Gene Symbol
BTLA
Additional BTLA Products
Product Documents for BTLA/CD272 Antibody (330104) [DyLight 594]
Product Specific Notices for BTLA/CD272 Antibody (330104) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...